Regular Aspirin Use May Lower Breast Cancer Risk

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirin or ibuprofen) regularly for 5 years or more had a 40% lower risk of breast cancer than those who did not report such use, Dr. Randall E. Harris and his colleagues at the Ohio State University Comprehensive Cancer Center have found.

COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirinor ibuprofen) regularly for 5 years or more had a 40% lower riskof breast cancer than those who did not report such use, Dr. RandallE. Harris and his colleagues at the Ohio State University ComprehensiveCancer Center have found.

This case-control study involved 303 breast cancer patients diagnosedat the University's Arthur G. James Cancer Hospital and 906 controls(women who underwent screening mam-mography and had no detectablebreast disease). Risk factor data were collected by personal interviewsat the time of diagnosis or screening.

Significantly more women in the control group (27%) reported regularNSAID use than did the breast cancer patients (19%). Calculationof odds ratios showed a reduction in risk of 36% for those whotook NSAIDs three or more times a week for 6 months or more, anda reduction of 40% among those who used NSAIDs seven times a weekfor 5 years or more.

These results, published in Oncology Reports (2:591-592, 1995),are supported by an earlier study by Dr. Harris' team that matched744 newly diagnosed breast cancer patients with 767 controls drawnfrom hospital patients with medical conditions unrelated to breastcancer.

That study found a 37% reduction in breast cancer risk among womenwho reported using NSAIDs at least three times a week for at least5 years (Prev Med 24:119-120, 1995).

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.